Long-term exposure to peroxisome proliferator-activated receptor g (PPARg) agonists such as rosiglitazone induces browning of rodent and human adipocytes; however, the transcriptional mechanisms governing this phenotypic switch in adipocytes are largely unknown. Here we show that rosiglitazone-induced browning of human adipocytes activates a comprehensive gene program that leads to increased mitochondrial oxidative capacity. Once induced, this gene program and oxidative capacity are maintained independently of rosiglitazone, suggesting that additional browning factors are activated. Browning triggers reprogramming of PPARg binding, leading to the formation of PPARg ''superenhancers'' that are selective for brown-in-white (brite) adipocytes. These are highly associated with key brite-selective genes. Based on such an association, we identified an evolutionarily conserved metabolic regulator, Kruppel-like factor 11 (KLF11), as a novel browning transcription factor in human adipocytes that is required for rosiglitazone-induced browning, including the increase in mitochondrial oxidative capacity. KLF11 is directly induced by PPARg and appears to cooperate with PPARg in a feed-forward manner to activate and maintain the brite-selective gene program.
Obesity has reached pandemic proportions and poses a tremendous threat to human health. Current strategies for therapy aim at restoring the obesity-causing energy imbalance in humans by either decreasing energy uptake or increasing energy expenditure. In this regard, promising targets for treatment of human obesity are brown and ''beige/brite (brown in white)'' adipose tissues (Harms and Seale 2013) , which have been shown to be metabolically significant tissues in both rodents and adult humans (Kopecky et al. 1995; Guerra et al. 1998; Feldmann et al. 2009; Seale et al. 2011; Ouellet et al. 2012; Yoneshiro et al. 2013) . The expression of uncoupling protein 1 (UCP1) in residing adipocytes allows uncoupling of mitochondria and thereby conversion of fatty acids and glucose into heat.
Traditionally, UCP1-positive adipocytes in rodents have been distinguished into classical brown adipocytes from brown adipose tissue (BAT) and brite (Petrovic et al. 2010 )/beige (Ishibashi and Seale 2010 ) (hereafter termed brite) adipocytes from white adipose tissue (WAT) (Harms and Seale 2013) . Recently, several studies demonstrated that human adults have separate depots of brown(-like) adipocytes interspersed among white adipocytes in the supraclavicular, para-aortic, and suprarenal fat depots (Cypess et al. 2009; van Marken Lichtenbelt et al. 2009; Virtanen et al. 2009 ). It is currently unclear whether these human brown(-like) adipocytes more resemble the inducible brite adipocytes found in the WAT of mice rather than the classical brown adipocytes from BAT (Sharp et al. 2012; Wu et al. 2012; Cypess et al. 2013; Lidell et al. 2013) . Nevertheless, there is a growing clinical interest in understanding how brite adipocytes develop, especially since the emergence of brite adipocytes in WAT is associated with protection against obesity and metabolic dysfunctions in several rodent models (Seale et al. 2011; Cohen et al. 2014) .
The appearance of brite adipocytes can be induced by several different thermogenic stimuli, including cold and b-adrenergic stimulation (Cousin et al. 1992; Himms-Hagen et al. 1994 ). In addition, long-term exposure to synthetic ligands of peroxisome proliferator-activated receptor g (PPARg), a key activator of both white and brown adipocyte differentiation (Lefterova et al. 2014) , has been shown to promote the formation of functional brite adipocytes in cultures of rodent white adipocytes and in WAT (Fukui et al. 2000; Wilson-Fritch et al. 2004; Petrovic et al. 2010) . Interestingly, studies using human preadipocytes, including human multipotent adiposederived stem (hMADS) cells, indicate that the ability of PPARg agonists to induce functional brite cells is conserved in humans (Digby et al. 1998; Elabd et al. 2009 ). Mechanistically, it has been suggested that PPARg ligands induce brown/brite-selective genes by directly activating PPARg at nearby regulatory regions (Sears et al. 1996) . However, browning is not immediately induced (Petrovic et al. 2010; Haakonsson et al. 2013) , indicating that activation and stabilization of the brite adipocyte gene program by rosiglitazone requires activation of additional indirect effectors that may help reprogram the chromatin template. Candidates for such rosiglitazone-induced effectors have been identified in rodents and include the cofactors PGC-1a (Hondares et al. 2006 ) and PRDM16 . At present, however, these rosiglitazone-induced effectors remain elusive. Furthermore, little is known about the molecular mechanisms underlying browning of human adipocytes, and genome-wide insight into the transcriptional reprogramming of the genome and the transcriptional networks involved is completely lacking.
In this study, we characterized for the first time the transcriptional processes underlying browning of human adipocytes using a genome-wide approach. We show that this is associated with reprogramming of PPARg binding to form brite-selective PPARg superenhancers that appear to play a key role in activation of brite-selective genes. We identify the Kruppel-like factor 11 (KLF11) gene based on its association with a brite-selective PPARg superenhancer and show that KLF11 is a novel browning factor directly induced by rosiglitazone and required for the activation of brite-selective genes by rosiglitazone.
Results

Browning of human adipocytes stimulates a comprehensive stable gene program linked to mitochondrial oxidative capacity
To explore the transcriptional mechanisms underlying the browning process of human adipocytes, we exposed mature white hMADS adipocytes to the PPARg ligand, rosiglitazone, for 3 d (i.e., days 13-16 of differentiation) ( Fig. 1A) . As previously shown, rosiglitazone induces the expression of well-established brown/brite adipocyte markers (Elabd et al. 2009; Pisani et al. 2011 ) such as UCP1, CIDEA, ELOVL3, and DIO2, whereas expression of the common adipocyte markers PLIN1/2, SCD, and FASN as well as the degree of fat synthesis and lipid accumulation are comparable in white and brite adipocytes . Interestingly, once induced, the expression of brite-selective marker genes is maintained from day 16 to day 19 and further until day 23 independently of continued rosiglitazone administration (Fig. 1C,D) , indicating that a stable brite adipocyte gene program has been switched on. Establishment of a full brite phenotype requires long-term exposure to rosiglitazone, since a short 2-h pulse of rosiglitazone in mature hMADS adipocytes at day 13 is insufficient for full activation of UCP1 transcription (Supplemental Fig. S1D ), suggesting that the induction of additional factors are needed to effectively activate a brite gene program in hMADS adipocytes.
To examine the global transcriptional changes associated with browning of white adipocytes, we performed RNA sequencing (RNA-seq) in hMADS preadipocytes as well as in mature white and brite hMADS adipocytes deprived of rosiglitazone. Principal component analysis based on gene expression profiles showed that preadipocytes and white and brite hMADS adipocytes separate into three clusters corresponding to distinct cell types (Supplemental Fig. S2A ). Comparison of white and brite adipocytes identified a total of 2829 differentially expressed genes (false discovery rate [FDR] < 0.05), of which 1691 are brite-selective and 1138 are white-selective ( Fig. 1E ; Supplemental Fig. S2B ). Notably, several known white and brown/brite marker genes are differentially expressed between white and brite hMADS adipocytes (Fig. 1F ). The gene programs that are selective for brite adipocytes are associated with increased mitochondrial function and energy consumption ( Supplemental Table S1 ; Supplemental Fig. S2C ). Importantly, this leads to a significant increase in basal, maximal, and uncoupled respiration in brite compared with white adipocytes, which is maintained in rosiglitazone-deprived brite adipocytes at day 19 ( Fig. 1G) . In contrast, genes selectively expressed in white hMADS adipocytes belong to pathways associated with amino acid metabolism ( Supplemental Table S1 ). Taken together, these results demonstrate that distinct ''stable'' gene programs are active in white and brite hMADS adipocytes and that the brite-selective gene program is associated with functional properties of the brite adipocytes.
Cell type-selective PPARg binding correlates with active chromatin signatures and cell type-selective gene expression
To determine the degree of reprogramming of the chromatin template and identify putative active chromatin regions (Crawford et al. 2006) , we generated genome-wide DNase I-hypersensitive (DHS) site profiles in white and brite hMADS adipocytes. Notably, despite considerable changes in gene expression during browning, the DHS profiles overall were very similar in white and brite adipocytes (Supplemental Fig. S3A,B) , indicating that the transcriptional changes during browning occur without major changes in the chromatin landscape.
We and others have recently shown the existence of robust fat depot-selective binding of PPARg linked to depot-specific gene expression in mice (Siersbaek et al. 2012; Rajakumari et al. 2013) , indicating that PPARg, in addition to its role as a general activator of adipogenesis in mice (Lefterova et al. 2008; Nielsen et al. 2008 ) and humans (Mikkelsen et al. 2010; Schmidt et al. 2011; Soccio et al. 2011) , plays a prominent role in the induction of genes characteristic of different adipocyte lineages. The fact that browning is induced by the PPARg ligand rosiglitazone indicates that PPARg is also a major driver of the genomic reprogramming during browning. To investigate this, we generated PPARg chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq) profiles in white and brite hMADS adipocytes. From a total of 52,030 PPARg-binding sites, we identified 4439 reprogrammed PPARg-binding sites with differential PPARg-binding intensity (FDR < 0.1) in white and brite adipocytes (2228 white-selective and 2211 briteselective) ( Fig. 2A ). Furthermore, we defined a group of 2385 constant sites that show comparable PPARg-binding signal in these two cell populations. Notably, levels of PPARg protein are comparable in brite and white adipocytes (Supplemental Fig. S4A ). The fact that <10% of the total number of PPARg-binding sites is reprogrammed indicates that most of the transcriptional functions of PPARg are maintained in the brite adipocytes. Nevertheless, reprogrammed PPARg-binding sites are high-intensity sites compared with the group of constant sites and thus are likely to represent key regulatory elements (Supplemental Fig. S4B ). De novo motif analysis did not show major differences in motif enrichment between the different groups of sites. The PPAR response element is the top-scoring motif in all three groups, whereas the NF1 half-site is enriched in white-selective and constant PPARgbinding sites, and the C/EBP motif is enriched in briteselective and constant PPARg-binding sites (Supplemental Fig. S4C ). To investigate the activity of these reprogrammed PPARg-binding sites, we evaluated the DHS sequencing (DHS-seq) profiles as well as ChIP-seq profiles of the subunit 1 of the Mediator complex (MED1), the coactivator CREB-binding protein (CBP), and the histone mark H3K27ac, all of which are known to be marks of active regulatory regions (Crawford et al. 2006; Heintzman et al. 2009; Creyghton et al. 2010; Kagey et al. 2010; Rada-Iglesias et al. 2011) . Interestingly, brite-selective PPARg-binding sites are found in regions that appear to be most active in brite adipocytes ( Fig. 2B; Supplemental Fig. S4D ). Similarly, white-selective PPARg-binding sites are found in regions with elevated activity in white adipocytes, whereas constant PPARg-binding sites display no major differences in activating chromatin marks between white and brite adipocytes. These results demonstrate that although no major overall changes occur in the chromatin template during browning, the reprogrammed PPARgbinding sites are associated with local remodeling of the chromatin and signatures of increased transcriptional activity. The role of PPARg as a major determinant of enhancer activity is supported by the fact that PPARg binding positively correlates with activating enhancer signatures at all identified PPARg-binding sites (Supplemental Fig. S5A ). Interestingly, the cell type-selective PPARg-binding events are highly enriched near cell typeselective genes (Fig. 2C ), including brite-selective genes such as UCP1 and ACSL5 ( Fig. 2D,E; Supplemental Fig. S5B ). Thus, these genome-wide analyses extend previous results based on single genes and indicate that PPARg is a critical direct activator of the brite-selective gene program.
Brite-selective PPARg superenhancers are highly enriched near brite-selective genes
It has recently been shown that superenhancers (i.e., clusters of enhancers) constitute particularly powerful regulatory nodes controlling expression of genes defining cell identity (Loven et al. 2013; Whyte et al. 2013) . To identify such key regulatory regions in hMADS adipocytes and determine whether they change during browning, we merged all identified PPARg-binding sites in close proximity (within 12.5 kb from each other) and ranked them according to the intensity of their associated MED1 signal. Using this approach, we identified 1106 PPARg superenhancers in brite adipocytes that have elevated levels of MED1 signal compared with regular PPARgbinding regions in two independent biological replicates ( Fig. 3A) . Compared with regular PPARg enhancers, the constituent PPARg-binding regions within PPARg superenhancers are enriched in MED1, H3K27ac, DHS, and CBP signal ( Fig. 3B; Supplemental Fig. S6A ), indicating that the constituent PPARg enhancers in superenhancers are significantly more active than regular PPARg enhancers. Furthermore, the PPARg signal intensity is higher in the PPARg superenhancer constituents compared with regular PPARg-binding regions, indicating that PPARg plays an active role in the formation of superenhancers.
To identify key cell type-selective regulatory regions, we examined PPARg superenhancers with differential MED1 signal in white and brite adipocytes. From a total of 1212 superenhancers identified in white and/or brite adipocytes, we identified 304 white-selective and 324 brite-selective (FDR < 0.01) as well as 148 constant PPARg superenhancers ( Fig. 3C ). Interestingly, brite-and white-selective PPARg-binding sites are highly enriched in brite-and white-selective superenhancers, respectively ( Fig. 3D ). Furthermore, PPARg-binding intensity is significantly higher at brite-selective sites than nonreprogrammed PPARg sites within brite-selective superenhancers (Supplemental Fig. S6B ). This indicates that superenhancers with cell type-selective activity arise as a consequence of PPARg reprogramming during the browning process. This is further supported by the fact that within these superenhancers, the increase in MED1 and H3K27ac signal in brite compared with white adipocytes is more pronounced at enhancer constituents where there is briteselective binding of PPARg compared with enhancer constituents where PPARg binding is independent of cell type (Supplemental Fig. S6C ).
Annotation of PPARg superenhancers to the nearest genes showed that cell type-selective PPARg superenhancers are highly enriched in the vicinity of cell typeselective genes and that the enrichment is much higher than for regular cell type-selective PPARg enhancers ( Fig. 3E) . Notably, brite-selective genes associated with brite-selective superenhancers are induced significantly more during browning and are expressed at much higher levels compared with brite-selective genes that do not have a super-enhancer associated with them ( Fig. 3F ). Furthermore, brite-selective genes associated with briteselective superenhancers belong to brite-selective metabolic pathways, such as fatty acid degradation and b-oxidation (Supplemental Fig. S7A ). Several of these metabolic genes are also marked by brite-selective PPARg superenhancers defined by H3K27ac signal (Supplemental Fig. S7B ). Examples of prominent brite-selective genes associated with brite-selective superenhancers are PDK4, ACSL5, CIDEA, and DIO2, whereas common PPARg superenhancers are found near general adipocyte genes such as PLIN1/2 and SCD1 ( Fig Rosiglitazone treatment induces the superenhancerassociated gene KLF11 in human adipocytes and subcutaneous fat of human type 2 diabetic (T2D) patients Superenhancers have been reported to be associated with genes that define cellular function (Whyte et al. 2013 ). In line with this, we identified common white and brite PPARg superenhancers associated with key adipocyte regulatory factors, including C/EBPb, PPARg, and STAT5A. To search for novel transcriptional mediators of the rosiglitazoneinduced browning of human adipocytes, we examined the genes associated with a brite-selective PPARg superenhancer (see Supplemental Fig. S7B for examples). Interestingly, we observed a prominent brite-selective PPARg superenhancer (as determined by both MED1 and H3K27ac ranking) near the gene encoding KLF11 ( Fig. 4A ; Supplemental Fig. S7B ,E). KLF11 (also called MODY7) is a well-known regulator of pancreatic b-cell function, and human genetic variants have been associated with dysfunctional b cells and diabetes (Neve et al. 2005; Bonnefond et al. 2011 ). In nonadipocyte cell lineages, KLF11 regulates several metabolic gene networks and acts as both an activator and a repressor of transcription (Fernandez-Zapico et al. 2009; Seo et al. 2012; Lomberk et al. 2013 ). Moreover, it was recently shown that KLF11 can activate UCP1 expression in mouse bone marrow-derived stem cells (Yamamoto et al. 2010) , suggesting that KLF11 could be a browning factor. However, whether and how it functions as such in mice are unclear. Furthermore, its role in human adipocytes remains totally unknown.
Consistent with the association of KLF11 with a briteselective PPARg superenhancer, we found that KLF11 is expressed at higher levels in brite compared with white adipocytes and that this level is maintained at least until day 23 ( Fig. 4B; Supplemental Fig. S8A,B ). Furthermore, we found compelling evidence that KLF11 is directly activated by PPARg during browning of human adipocytes. First, we showed that the expression of KLF11 in brite adipocytes is dependent on PPARg ( Fig. 4C ; Supplemental Fig. S8C ). Second, treatment of mature brite adipocytes with the selective PPARg antagonist GW9662 leads to an acute reduction of KLF11 pre-mRNA levels (Supplemental Fig. S8D ). Third, KLF11 pre-mRNA levels are significantly induced only 2 h after rosiglitazone treatment of mature hMADS adipocytes, and this increased transcription is maintained in mature brite adipocytes (Fig. 4D ). Collectively, these results indicate that KLF11 is a brite-selective factor directly induced by PPARg in hMADS adipocytes, most likely as a result of PPARg binding to clusters of binding sites in the vicinity of the gene.
It has recently been demonstrated that cooling of white and brite murine adipocytes activates a b-adrenergicindependent thermogenic gene program (Ye et al. 2013) . Interestingly, brite (Supplemental Fig. S8E ) but not white hMADS adipocytes (data not shown) respond to 4 h of cooling at 31°C by an increase in the expression of UCP1 and a subset of other brite-selective genes, including KLF11. Furthermore, b-adrenergic stimulation of brite (Supplemental Fig. S8F ) but not white hMADS adipocytes (data not shown) leads to a modest increase in UCP1 and KLF11. This demonstrates that although these thermogenic stimuli are insufficient for induction of browning per se, they lead to further activation of KLF11 along with the brite-selective gene program in brite hMADS adipocytes.
Next, we examined whether rosiglitazone treatment of human adults has any effect on KLF11 expression in subcutaneous fat. For this purpose, we used a human cohort consisting of 18 T2D patients treated with rosiglitazone for 90 d (Tan et al. 2005) . Interestingly, rosiglitazone treatment leads to a statistically significant induction of KLF11 expression in abdominal subcutaneous fat of T2D subjects compared with placebo treatment (Fig. 4E ). UCP1 expression was below the detection limit in 16 out of 18 placebo-treated individuals in this cohort; however, upon 90 d of rosiglitazone treatment, UCP1 expression became detectable in eight out of 18 T2D patients (Supplemental Fig. S8G ), suggesting that some degree of browning occurs in the subcutaneous fat in response to rosiglitazone. Taken together, this demonstrates that KLF11 is a direct PPARg target gene that is induced by rosiglitazone during in vitro as well as in vivo browning of human adipocytes.
KLF11 specifically activates the brite adipocyte gene program
We next addressed whether KLF11 plays an active role in the regulation of the human brite adipocyte gene program. Using two different lentiviral shRNA constructs, we found that knockdown of KLF11 in mature hMADS adipocytes significantly inhibits the induction of UCP1 upon rosiglitazone stimulation (Fig. 5A,B) . In contrast, knockdown of a white-selective factor, ZNF323, resulted in a robust induction of UCP1 mRNA expression compared with the scramble control (Supplemental Fig. S9A) . Consistent with the effect on UCP1 expression, we found that a subset of functionally important brite-selective genes is significantly repressed by KLF11 knockdown, whereas a control group consisting of white and general adipocyte marker genes is not (Fig. 5B ). Importantly, PPARg expression is comparable in control cells and cells with knockdown of KLF11, demonstrating that the effect on brite-selective gene expression is not mediated by feedback regulation of PPARg (Fig. 5A,B) . Interestingly, the gene encoding FHL1 is also associated with a briteselective superenhancer (Supplemental Fig. S9B,C) , and we show that FHL1, similar to KLF11, is required for browning ( Supplemental Fig. S9D ). This demonstrates that brite-selective superenhancers can be used as a discovery tool to identify key regulatory factors for the browning process.
Investigation of the global effect of KLF11 on the briteselective gene program by RNA-seq (Supplemental Fig.  S10A ) showed that a large fraction of brite-selective genes (17.4%) is significantly repressed by KLF11 knockdown, whereas a significantly lower fraction (4.3%) is induced. Furthermore, only minor fractions of white-selective and constitutively expressed genes are affected by KLF11 knockdown (Fig. 5C ). These results indicate that KLF11 acts predominantly as an activator of the brite-selective gene program. Notably, functional enrichment analysis WAT from a total of 18 subjects treated for 3 mo with placebo and then 3 mo with rosiglitazone or vice versa. mRNA expression was normalized to control genes PPIA and PGK1. Details on the human cohort were previously described (Tan et al. 2005 Cold Spring Harbor Laboratory Press on January 23, 2020 -Published by genesdev.cshlp.org Downloaded from revealed that the majority of genes repressed by KLF11 knockdown belong to brite-selective metabolic pathways ( Supplemental Table S1 ), such as fatty acid metabolism and oxidative phosphorylation (Fig. 5D) . Importantly, the ability of rosiglitazone to induce a higher oxygen consumption rate (OCR; i.e., basal, maximal, and uncoupled respiration) and fatty acid oxidation capacity is completely abolished by KLF11 knockdown (Fig. 5E; Supplemental Fig. S10B ). Thus, KLF11 is required for the ability of rosiglitazone to induce a brite phenotype in hMADS adipocytes.
To investigate whether KLF11 is capable of further activating brite-selective genes, we modestly overexpressed KLF11 in brite hMADS adipocytes using an adenoviral vector ( Fig. 5F ) and evaluated the effects on the subset of genes examined in Figure 5, A and B . Interestingly, overexpression of KLF11 causes a significant increase in mRNA levels of the majority of these brite-selective genes ( Fig. 5F; Supplemental Fig. S10C ), whereas there is little effect on general and white adipocyte marker genes. Collectively, these results show that KLF11 plays an important and rate-limiting role in the induction of the brite-selective gene program and an oxidative phenotype in hMADS adipocytes.
KLF11 induces brite-selective genes by activating nearby regulatory regions
To address the question of whether KLF11 directly activates brite-selective genes, we investigated whether KLF11 occupies sites in the vicinity of brite-selective genes regulated by KLF11. Antibody specificity was validated by KLF11 knockdown followed by ChIP-qPCR at selected sites (Supplemental Fig. S11A ). Interestingly, we detected significant KLF11 binding in close proximity to several brite-selective genes, including UCP1, PDK4, FABP3, and DIO2, in brite hMADS adipocytes (Fig. 6A ). Genome-wide binding profiling of KLF11 in white and brite hMADS adipocytes identified a total of 38,391 binding sites. As reported for KLF1 (Pilon et al. 2011 ), KLF11 binding is most prominent at gene promoter regions, although robust binding to distal regions can also be detected (Fig. 6B) . Importantly, however, there is a highly significant enrichment of a motif resembling the SP1/KLF motif in all of these groups, suggesting that KLF11 binds directly to both promoter and more distal sites (Supplemental Fig. S11B ). Interestingly, KLF11 binding at PPARg enhancer constituents within superenhancers in brite adipocytes is elevated compared with that at regular PPARg enhancers (Fig. 6C) , indicating that KLF11 is particularly associated with PPARg in superenhancers. Coimmunoprecipitation of KLF11 and PPARg in brite hMADS adipocytes showed that they are able to interact, indicating potential direct cooperativety between these Fig. S11C ). In line with this, KLF11 knockdown reduces MED1 occupancy at a subset of shared PPARg/KLF11-binding sites within brite-selective PPARg superenhancers (Supplemental Fig. S11D ), indicating that KLF11 affects the activity of at least a subset of PPARg constituents within briteselective PPARg superenhancers.
To identify the functionally most important KLF11binding sites, we performed H3K27ac ChIP-seq in hMADS adipocytes with or without KLF11 knockdown and evaluated the changes in H3K27ac signal upon KLF11 knockdown at all identified KLF11-binding sites. This allowed us to define subsets of KLF11-binding sites that either lose (1179 sites), gain (489 sites), or have unchanged (1076 sites) H3K27ac levels in response to KLF11 knockdown ( Supplemental Fig. S12A) ; i.e., sites representing putative KLF11-activated, KLF11-repressed, and unaffected sites, respectively. Interestingly, the percentage of distal KLF11-binding sites affected by KLF11 knockdown is significantly higher than the percentage of promoterproximal sites affected, suggesting that KLF11 has a prominent effect on distal regions despite these being weaker binding sites (Supplemental Fig. S12B ).
We next examined how these responsive KLF11-binding sites are related to brite-and white-selective gene programs. Interestingly, we found that the fraction of brite-selective genes associated with putative KLF11activated binding sites is significantly higher than the fraction of white-selective and constitutively expressed genes (Fig. 6D ). Furthermore, putative KLF11-activated binding sites are enriched in the vicinity of brite-selective genes compared with KLF11-repressed and unaffected binding sites and are even more enriched near briteselective genes that are repressed by KLF11 knockdown (Fig. 6E) . In contrast, such sites are not enriched near genes that are induced by KLF11 knockdown or near white-selective genes (Supplemental Fig. S12C ). These results demonstrate that KLF11-activated sites are mainly linked to brite-selective genes (see Fig. 6F ; Supplemental Fig. S12D for examples) . Importantly, there is a positive correlation between changes in KLF11 signal and H3K27ac signal during browning at KLF11-activated sites (Fig. 6G) , with a specific gain of KLF11 and H3K27ac near brite-selective compared with white-selective genes ( Fig. 6H; Supplemental Fig. S12E ). Cumulatively, these results indicate that KLF11 functions as a specific and direct transcriptional activator of a large subset of briteselective genes.
In summary, we present a model (Fig. 7) for rosiglitazone-mediated browning of human adipocytes and show the requirement for KLF11 in this process. In this model, rosiglitazone stimulation of mature human adipocytes triggers reprogramming of PPARg binding, leading to the formation of brite-selective PPARg superenhancers, which play an important role in activating the brite-selective gene program. This includes genes encoding browning transcription factors such as KLF11, which act in a cooperative manner with PPARg to ensure full induction and maintenance of the brite adipocyte gene program independently of rosiglitazone.
Discussion
In this study, we used for the first time a genome-wide approach to characterize the transcriptional reprogramming events associated with the formation of functional human brown-like adipocytes. Using rosiglitazone as a browning stimulus, we show that comprehensive transcriptional changes occur during the browning process to establish a stable brite adipocyte gene program that, once established, can be maintained independently of rosiglitazone. Thus, it appears that the prolonged rosiglitazone stimulus induces an alternatively committed differentiation state in hMADS cells, where the adipocytes remain brite even when the stimulus has been withdrawn. This indicates that additional ''stabilizing'' browning factors are induced by rosiglitazone and are required for maintenance of browning.
Interestingly, rosiglitazone is also used in the differentiation cocktail from day 3 to day 9 of hMADS differentiation, at which point browning is not induced. It is unclear why only mature white adipocytes are able to undergo browning in response to rosiglitazone, but it is likely that activation of the browning genes requires factors that are not expressed until late in the differentiation of white adipocytes.
Despite considerable changes in gene expression during browning, the genome-wide changes in DHS are modest. This is in sharp contrast to the dramatic changes in chromatin structure (Siersbaek et al. 2011; Waki et al. 2011 ) and epigenomic marks (Mikkelsen et al. 2010; Steger et al. 2010 ) during 3T3-L1 adipocyte differentiation and indicates that transcriptional changes during browning of hMADS cells occur without major global changes in the chromatin landscape. Instead, our results indicate that browning relies on changes of the activity of a small subset of enhancers, possibly combined with modest changes in the activity of additional enhancers.
The fact that browning is induced by rosiglitazone indicated that PPARg could be a major driver of the genomic reprogramming during browning, and we therefore profiled PPARg in white and brite hMADS adipocytes. We showed that only a small fraction of PPARg-binding sites differs dramatically in PPARg occupancy, indicating that PPARg acts in a site-selective manner and that the majority of PPARg functions are common between white and brite adipocytes. Similarly, PPARg binding in in vitro differentiated primary adipocytes obtained from different mouse white and brown adipose depots differs only at a subset of sites (Siersbaek et al. 2012) . Importantly, and consistent with a central role of PPARg in genomic reprogramming, we show that reprogrammed brite-selective PPARg-binding sites correspond to sites that gain enhancer activity during browning, and these sites are enriched in the vicinity of brite-selective genes.
Interestingly, reprogramming of PPARg binding during browning leads to the formation of brite-selective superenhancers (i.e., clusters of individual enhancers) recently shown to be key drivers of gene programs that define cell identify (Loven et al. 2013; Whyte et al. 2013 ). It appears that reprogramming of PPARg binding at single constituent enhancers plays a major role in redefining PPARg superenhancers during browning. Importantly, we show that brite-selective PPARg superenhancers are much more enriched near brite-selective genes than regular brite-selective PPARg enhancers. Furthermore, briteselective genes associated with brite-selective superenhancers are more dramatically induced during browning than genes that do not have brite-selective superenhancers nearby. This clearly indicates the importance of superenhancers in defining gene programs characteristic of different adipocyte subtypes. The brite-selective superenhancers are enriched near genes encoding important metabolic regulators involved in fatty acid degradation and b-oxidation.
Since superenhancers have been reported to be associated with genes encoding lineage-determining transcriptional regulators (Whyte et al. 2013) , we examined the list of genes associated with brite-selective PPARg superenhancers. Interestingly, both factors that were chosen for analysis, KLF11 and FHL1, were found to be required for browning, demonstrating that association with superenhancers can be used as a discovery tool to identify novel transcriptional regulators of browning of adipocytes. Here we selected KLF11, which is a member of the SP1/KLF family of transcription factors, for further analyses. KLFs constitute an interesting family of tran-scription factors involved in the regulation of diverse metabolic networks (Neve et al. 2005; Lomberk et al. 2013; Zhang et al. 2013) . Several KLF family members, including KLF2, KLF3, KLF4, KLF5, KLF6, KLF7, KLF9, and KLF15, have been implicated in different stages of adipogenesis (Wu and Wang 2013) , but a role of KLF11 in adipogenesis has not been described. KLF11 has been shown to activate UCP1 expression in mouse bone marrow-derived stem cells (Yamamoto et al. 2010) ; however, the impact of KLF11 on browning of adipocytes remains unknown.
Our results identify KLF11 as a novel PPARg target gene in human adipocytes, presumably activated through the nearby PPARg superenhancer. Importantly, we show by loss of function and gain of function that KLF11 is a selective global activator of the brite adipocyte gene program in human adipocytes. To our knowledge, this places KLF11 as the first PPARg-induced sequence-specific transcription factor involved in browning. Thus, KLF11 acts as a direct molecular link between the acute rosiglitazone-induced gene program and stabilization of the brite adipocyte phenotype. Cofactors that may contribute to this link include PGC-1a, which is a PPARg target gene in primary cultures of white and brown adipocytes (Hondares et al. 2006) , and PRDM16, which has been shown to be activated by PPARg through increased stability . Interestingly, our data show that KLF11 can be further induced by cooling and b-adrenergic stimulation of brite hMADS adipocytes, suggesting that KLF11 might be involved in mediating alternative thermogenic stimuli in addition to rosiglitazone-induced browning. In support of this notion, examination of microarray data from mice subjected to cold for 10 d (Rosell et al. 2014) revealed that KLF11 expression is induced in subcutaneous WAT as part of the cold response involving thermogenic and oxidative genes. In line with what has previously been shown (Elabd et al. 2009; Jespersen et al. 2013) , neither b-adrenergic stimulation nor cooling of white hMADS adipocytes is capable of inducing browning, suggesting that additional activation stimuli are needed for induction of a thermogenic response in human white adipocytes.
Browning of human adipose tissue in response to cold has been shown to contribute significantly to human metabolism (Ouellet et al. 2012; Yoneshiro et al. 2013) , and it is likely that rosiglitazone-induced browning of human adipose tissue could have a similar effect (Bogacka et al. 2005) . Interestingly, our results show that KLF11 expression is induced by rosiglitazone in abdominal subcutaneous adipose tissue of human T2D subjects and that this is paralleled by an induction of UCP1 to detectable levels in eight out of 18 subjects. Thus, in addition to the weight gain experienced in subjects treated with rosiglitazone in this cohort (Tan et al. 2005) , our data indicate that at least a subset of these patients displayed modest browning of their subcutaneous adipose tissue in response to rosiglitazone.
Genome-wide profiling of KLF11 demonstrates that KLF11 is primarily associated with promoter-proximal regions, which is in line with results for another member of the SP1/KLF family, KLF1 (Pilon et al. 2011 ). Since KLF11 has been reported to have both Sin3-HDACdependent and HP1-HMT-dependent repressor functions as well as p300-induced activation properties (Zhang et al. 2001; Fernandez-Zapico et al. 2009; Lomberk et al. 2012; Seo et al. 2012) , we grouped the KLF11-binding sites into putative KLF11-activated sites (loss of H3K27ac in response to KLF11 knockdown) and putative KLF11-repressed sites (gain of H3K27ac in response to KLF11 knockdown). Our results demonstrate that putative KLF11-activated binding sites are highly enriched in the vicinity of brite-selective genes, in particular putative KLF11-activated brite-selective genes. A similar enrichment of KLF11-repressed sites was not observed for genes activated by loss of KLF11. This indicates that, in terms of the browning process, KLF11 acts primarily as a direct activator of the brite gene program.
In conclusion, we show for the first time that rosiglitazone-induced browning of human adipocytes is associated with comprehensive changes in gene expression driven in part by brite-selective PPARg superenhancers. Furthermore, we identify KLF11 as a novel browning factor and a direct PPARg target gene that is required for rosiglitazone-induced browning of human adipocytes. Thus, KLF11 constitutes a novel molecular link between the rosiglitazone-induced gene expression and the activation and maintenance of the brite-selective gene program. We propose that activation of KLF11 and other browning factors cooperate with PPARg to establish a ''stable'' brite phenotype independent of continued administration of rosiglitazone. Future studies should investigate the molecular cross-talk between PPARg and such browning factors.
Materials and methods
hMADS cell culturing and differentiation hMADS-3 cells (Rodriguez et al. 2005; Zaragosi et al. 2007 ) were cultured and differentiated into mature adipocytes as described in the Supplemental Material. From day 13 to day 16 of differentiation, hMADS adipocytes were treated with rosiglitazone to form brite adipocytes or with DMSO to maintain white adipocytes. From day 16 forward, the differentiation medium of both white and brite adipocytes was depleted for rosiglitazone. GW9662 (Sigma) at 0.5 mM and isoproterenol (Sigma) at 1 mM were applied to the cell cultures as indicated.
Oil-red-O staining and glycerol-3-phosphate dehydrogenase analysis
Oil-red-O staining was performed as previously described (Helledie et al. 2002) . Spectrophotometric analysis was used for quantification by measuring optical density at 500 nm. Glycerol-3-phosphate dehydrogenase activity measurements were performed as previously described (Negrel et al. 1978) .
RNA extraction, cDNA synthesis, and quantitative real-time PCR RNA extraction, cDNA synthesis, and quantitative real-time PCR were performed as previously described (Nielsen et al. 2006) . Data were normalized to TBP unless stated otherwise. Sequences of real-time PCR primers will be provided on request. Two-tailed Student's t-test was used to determine significance.
Western blotting and ECL detection
Whole-cell extracts were prepared in SDS-containing buffer and subjected to Western blotting as previously described (Nielsen et al. 2006 ). The following antibodies were used: anti-PPARg (E-8; sc-7273, Santa Cruz Biotechnology), anti-KLF11 (10D8; H00008462-M03, Novus Biologicals), anti-FHL1 (10991-1-AP, Proteintech), anti-UCP1 (ab10983, Abcam), anti-Omni-probe (D8; sc-7270, Santa-Cruz Biotechnology), anti-rabbit IgG (P0399, DAKO), and anti-mouse IgG (P0447, DAKO). Anti-SP1 (sc-17824, Santa-Cruz Biotechnology) or anti-TFIIB (sc-225, Santa Cruz Biotechnology) was included as a loading control. Densitometry was used to quantify protein expression, and a two-tailed Student's t-test was used to determine significance.
Lentiviral production and transduction of hMADS cells
For knockdown of PPARg (Nielsen et al. 2008) , KLF11, FHL1, and ZNF323 shRNA oligos targeting these factors were cloned into pSicoR PGK puro vectors (Addgene), and lentiviral particles were produced in human embryonic kidney (HEK) 293T cells as described (Ventura et al. 2004) . As a control, a shRNA nontargeting oligo (scramble) was used. Sequences of shRNA oligos will be provided on request. Mature hMADS adipocytes (day 10 after induction of differentiation) were incubated for 24 h with lentiviral medium containing 6 mg/mL polybrene (Sigma) before the medium was changed to normal differentiation medium. shKLF11 construct #1 was used for RNA-seq experiments.
Adenoviral overexpression
The generation of the (His 6 -Xpress) KLF11 and control adenoviral vectors (Ad5CMV) was described in Lomberk et al. (2012) . Rosiglitazone-treated hMADS adipocytes at day 15 were transduced for 6 h with ;8 3 10 9 infectious units of adenoviral particles per milliliter and 1 mg/mL poly-L-lysine in DMEM (Sigma). After the initial incubation, the medium was changed to normal differentiation medium without rosiglitazone, and cells were harvested 18 h later.
b-Oxidation
Determination of b-oxidation capacity in day 16 hMADS adipocytes transduced with lentivirus as described above was performed essentially as previously described (Berge et al. 2003) .
Mitochondrial respiration analyses
For mitochondrial respiration analysis, hMADS cells were seeded in 24 multiwell plates (Seahorse) and differentiated and/ or transduced with lentivirus as previously described. OCR in hMADS adipocytes at day 16 or 19 was determined using an XF24 extracellular flux analyzer (Seahorse Bioscience). We added 1.2 mM oligomycin, 1 mM FCCP, 1 mM rotenone, and 1 mM antimycin A to the cells as indicated.
Coimmunoprecipitation
Nucleus extraction and coimmunoprecipitation were performed essentially as described (Siersbaek et al. 2014) . In brief, nuclei were isolated from rosiglitazone-treated hMADS adipocytes transduced with AdEV or His-tagged AdKLF11 as described above. Cleared nuclear extract was subjected to coimmunoprecipitation overnight at 4°C using anti-Omni-probe (D8; Santa-Cruz Biotechnology, sc-7270) conjugated to agarose beads. After washing, the immunoprecipitates were eluted by boiling in SDS buffer and subsequently prepared for Western blotting.
RNA-seq
Five micrograms of total RNA from hMADS preadipocytes and mature day 19 white and brite adipocytes was treated with a Ribo-Zero rRNA removal kit (Epicentre) and subjected to fragmentation and cDNA synthesis using the TruSeq RNA sample preparation kit version 2 (Illumina).
ChIP
ChIP experiments were performed in white and brite hMADS adipocytes at day 19 essentially as previously described (Siersbaek et al. 2012) . For cross-linking of chromatin, 0.2 mM disuccinimidyl glutarate (DSG) (Proteochem) was applied for 45 min followed by cross-linking using 1% formaldehyde for 10 min. The antibodies used were anti-PPARg (H-100; sc-7196, Santa Cruz Biotechnology), anti-MED1 (M-255; sc-8998, Santa Cruz Biotechnology), anti-CBP (A-22; sc-369, Santa Cruz Biotechnology), anti-KLF11 (10D8; H00008462-M03, Novus Biologicals), and anti-H3K27ac (ab4729, Abcam).
DHS site assessment
DNase I digestion was performed in white and brite hMADS adipocytes at day 19 on ;10 million nuclei essentially as previously described (Siersbaek et al. 2011) .
Library construction
RNA-seq, DHS-seq, and ChIP-seq libraries were constructed according to the manufacturer's instructions (Illumina) as described . Sequencing was performed on our in-house Illumina platform.
Data analyses
RNA-seq data RNA reads were aligned to the human reference genome (version hg19) using Bowtie2 (Langmead and Salzberg 2012) . The number of exon reads for all RefSeq genes was counted using Subread (Liao et al. 2013) , and differential expression was determined using DESeq2 (Love et al. 2014) . Functional enrichment analysis was performed with HOMER (Heinz et al. 2010) using pathways related to metabolism from the Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation (Kanehisa and Goto 2000; Kanehisa et al. 2014) Alignment of ChIP-seq and DHS-seq data, peak calling, and identification of regions with differential signal intensity Sequence tags were aligned to the human reference genome (hg19) using Bowtie (Langmead et al. 2009 ), and ChIP-seq peaks were called using HOMER (Heinz et al. 2010) . The University of California at Santa Cruz Genome Browser (Kent et al. 2002) was used for visualization. The differential signal intensity in binding regions/superenhancers was determined using HOMER and EdgeR (Robinson et al. 2010) .
Accession numbers Sequencing data are available from the Gene Expression Omnibus (GEO) under accession number GSE59703.
Human subjects
Human subcutaneous abdominal fat biopsies from a double-blind, placebo-controlled, crossover study involving T2D subjects treated with placebo/rosiglitazone for 90 d were used to analyze KLF11 expression. A total of 18 subjects from whom a complete physiological data set is available was included. Details on subjects and procedures were as described previously (Tan et al. 2005) . Significance was determined using a Wilcoxon matched pairs signed-ranks test.
Additional information is available in the Supplemental Material.
